A New Frontier for Surgical Visualization In a significant development for surgical oncology, Alume Biosciences has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to their investigational agent, bevonescein. This milestone marks a pivotal step in improving the standard of care for patients undergoing surgical procedures. What is Bevonescein?…